SBI Securities’s Palvella Therapeutics PVLA Stock Holding History

SBI Securities’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12	Closed	-$270	–	4343
2025 Q2	$270	Buy	+12	New	+$282	﹤0.01%	3222

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SBI Securities's PVLA Position: Q3 2025 in Review

SBI Securities sold out of Palvella Therapeutics (PVLA) in Q3 2025, closing a stake of 12 shares — an estimated $270 sold.

SBI Securities first reported a position in PVLA in Q2 2025 and held it in 1 quarter. The position peaked at $270 in Q2 2025. 100 funds tracked by Wall St. Rank hold PVLA as of Q3 2025.

SBI Securities reported no remaining Palvella Therapeutics position as of Q3 2025 after selling out during the quarter.
SBI Securities sold 12 Palvella Therapeutics shares in Q3 2025, an estimated $270.
SBI Securities first reported a position in Palvella Therapeutics in Q2 2025 and held it in 1 quarter.
SBI Securities's Palvella Therapeutics position peaked at $270 in Q2 2025.
100 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.